MediCortex USA, Ltd. to present at The 4th Annual Traumatic Brain Injury Conference, APRIL 16-17, 20

Traumatic brain injury (TBI) is perhaps the most devastating physical trauma that the body can sustain, because TBI induces a chemical cascade which, if not halted, inexorably causes neurodegeneration. This process can last for weeks and even years, leading to TBI victims losing more and more of their physical and mental faculties.

How does this happen? Secondary brain injury in patients with either severe or mild TBI occurs as a result of increased permeability of the neuronal membrane, followed by an excessive influx of metal ions and circulating free radicals. This causes a series of protein degradation cascades and oxidation, leading to widespread molecular damage and neuronal cell death. This process can be fatal, but even when TBI does not result in death, the long term effects can be devastating, both for the victim and for their family. Extended hospitalizations are common, and often there is a need for rehabilitation, on-going treatment and care, and the intervention of welfare services.

As such, TBI represents both a tremendous medical concern as well as a huge economic burden worldwide. Moreover, with ever growing numbers of people around the world driving cars, participating in dangerous sports, fighting in wars, and even just living longer, the incidence of TBI is increasing rapidly. Yet despite the tremendous need for an effective TBI treatment, there is currently no drug available to address the progression of the secondary injury upon TBI.

Dr. Adrian Harel, MediCortex’s founder and CEO, stated: "We will present the scientific development plan for our new drug candidates, which are aimed at moderating the effects of TBI. The company has designed twelve chemically verified proprietary NCE’s"

More about TBI and the MediCortex Approach
The complexity of the post-TBI cascade is almost certainly the reason that all clinical trials to date have failed to meet their endpoints. Given that until now; all tested compounds have been single-target drugs, this is why MediCortex's multifunctional approach represents such a critical breakthrough in TBI treatment.

According to the National Centers for Disease Control (CDC), there are approximately two million TBI incidents in the US each year. Of these, over 50,000 result in death, and some 200,000 result in permanent neurological deficit. Worldwide, there are over 10 million TBI cases annually. That translates to more than a quarter of a million deaths, and over a million neurological deficit sufferers, all victims of TBI. Millions more suffer for months or even years before making full recoveries. During that time, the patients and their families undergo tremendous emotional, physical, and financial stress. There is a clear moral imperative to find an effective treatment for TBI, and MediCortex is ready to work with the medical community and all biotech companies that are seeking a solution to this huge unmet need.
Investors should obviously be keen to invest in an effective TBI treatment. Very conservative estimates predict that in the United States, the annual TBI therapeutics market will reach $2 billion by 2017. If one factors in the European and Asian markets, as well as the potential for prophylactic use in athletes, soldiers, and other at-risk groups, the market grows to a minimum of $10 billion annually. And if, as we predict, MediCortex's drugs prove useful in stroke, Alzheimer's, Parkinsons, and other neurodegenerative conditions, even $100 billion in sales is not at all out of the question. Simply put, the market potential for a family of drugs that could effectively block the neurodegenerative chemical cascade is nothing short of staggering.

About MediCortex
MediCortex (www.medicortex.com ) is an innovative biotechnology company developing breakthrough drug agents for the treatment of TBI, stroke, and other acute neurodegenerative conditions. The company's initial focus is on preventing secondary brain injury in TBI, a complex process caused by the multiplex biochemical changes which occur upon the primary injury. MediCortex's unique neuroprotective strategy is to introduce a multi-functional compound that addresses several biochemical and physiological pathways simultaneously. MediCortex is a privately held company founded in 2011 by Dr. Adrian Harel, an experienced neurobiologist with a solid track record in business management and in the leadership of early-stage drug discovery companies. His collaboration with renowned experts in medical chemistry ensures the development of a successful pipeline of innovative molecules for the treatment of acute neurodegenerative disorders.

About Kberg Consultants
"Kberg Consultants is pleased to partner with Medicortex USA to bring their novel treatments to patients in need. We have searched for a company that would allow us to enter into the clinical development space and have found that match with Dr. Adrian Harel and his brilliant team. This will compliment our already successful solutions for the Life Science industry from laboratory bench testing to manufacturing quality final products. Helping to advance the treatment of acute neurodegenerative disorders is a once in a life time opportunity and seeing patients regain their life functionality is what it's all about. Contact us to set up an appointment during the TBI Conference or following the meeting.

Cautionary Statement
This news release may contain forward-looking statements involving risks and uncertainties, Actual results may differ materially from the results anticipated in these forward-looking statements.

Contact:
Dr. Adrian Harel, CEO
e-mail: onomatop@netvision.net.il
www.medicortex.com
or
Stewart J. Kohnberg -Founder & CEO
Kberg Consultants
(m) 910.232.0342
www.KbergConsultants.com